Signals mining and analysis of adverse drug events of pazopanib based on FAERS database

BO Mingming; SHI Yafei; SUN Jixiong; WANG Tianyu; LI Guohui; DAI Yuanyuan

doi:10.6039/j.issn.1001-0408.2023.15.17

您当前的位置：

首页 >

文章列表页 >

Signals mining and analysis of adverse drug events of pazopanib based on FAERS database

更新时间：2023-08-10

- Signals mining and analysis of adverse drug events of pazopanib based on FAERS database
- ZHONGGUO YAOFANG Vol. 34, Issue 15, Pages: 1879-1883(2023)
- 作者机构：
  
  1.国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院药剂科，北京　100021
  2.国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院肿瘤医院廊坊院区药剂科，河北廊坊　065001
  3.国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院肿瘤医院廊坊院区信息管理中心，河北廊坊　065001
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2023.15.17
  CLC： R969.3
- Published：15 August 2023，
  
  Received：04 January 2023，
  
  Revised：20 July 2023，
扫描看全文
薄明明,石亚飞,孙继雄等.基于美国FAERS数据库的培唑帕尼不良事件信号挖掘与分析 ^Δ[J].中国药房,2023,34(15):1879-1883.

BO Mingming,SHI Yafei,SUN Jixiong,et al.Signals mining and analysis of adverse drug events of pazopanib based on FAERS database[J].ZHONGGUO YAOFANG,2023,34(15):1879-1883.
薄明明,石亚飞,孙继雄等.基于美国FAERS数据库的培唑帕尼不良事件信号挖掘与分析 ^Δ[J].中国药房,2023,34(15):1879-1883. DOI： 10.6039/j.issn.1001-0408.2023.15.17.

BO Mingming,SHI Yafei,SUN Jixiong,et al.Signals mining and analysis of adverse drug events of pazopanib based on FAERS database[J].ZHONGGUO YAOFANG,2023,34(15):1879-1883. DOI： 10.6039/j.issn.1001-0408.2023.15.17.

摘要

目的

挖掘并分析培唑帕尼上市后的药物不良事件（ADE）信号，为临床安全用药提供参考。

方法

通过OpenVigil 2.1数据平台对美国FDA药物不良事件报告系统（FAERS）数据库进行信号挖掘，收集培唑帕尼2009年10月－2022年6月的ADE报告，采用比例失衡法中的比例报告比值（PRR）法和报告比值比（ROR）法检测该药的ADE信号并进行分析。

结果

共筛选出以培唑帕尼为首要怀疑药物的ADE报告16 655份，经ROR法、PRR法挖掘出ADE信号220个，涉及19个系统器官分类。信号频度排前10位的ADE信号在该药的药品说明书中均有记载；发现了88个新的ADE信号，主要分布在胃肠系统、各种检查、肾脏和泌尿系统。嗜碱细胞数减少、甲床出血、肿瘤破裂、阴道瘘既是新的ADE信号，也是信号强度排前10位的ADE信号。

结论

培唑帕尼在上市后应用中常见ADE（腹泻、毛发颜色改变、高血压等）的发生情况与其药品说明书基本一致；新的可疑风险信号（嗜碱细胞数减少、甲床出血、肿瘤破裂、阴道瘘等）报道例数较少，还需持续关注。

Abstract

OBJECTIVE

To mine and analyze adverse drug event （ADE） signals after the marketing of pazopanib and provide references for clinically safe medication.

METHODS

OpenVigil 2.1 data platform was used to mine ADE signals from the US FDA adverse event reporting system （FAERS） database. ADE reports of pazopanib from October 2009 to June 2022 were collected， and ADE signals were analyzed using proportional reporting ratio （PRR） method and reporting odds ratio （ROR） method in the proportional imbalance method.

RESULTS

A total of 16 655 ADE reports were identified with pazopanib as the primary suspect drug. Through ROR and PRR analysis， 220 ADE signals involving 19 system organ classes were identified. The top 10 ADE signals by frequency were recorded in the drug instruction. Additionally， 88 new ADE signals were discovered， mainly related to the gastrointestinal system， various investigations， and the renal and urinary system. Decreased basophil count， nail bed hemorrhage， tumor rupture， and vaginal fistula were both new ADE signals and the top 10 ADE signals by strength.

CONCLUSIONS

The occurrence of common ADEs （diarrhea， hair color changes， hypertension， etc.） during the use of pazopanib after marketing is generally consistent with its drug instruction； the number of reported cases for new suspected risk signals （decreased basophil count， nail bed hemorrhage， tumor rupture， and vaginal fistula， etc.） is limited， and continuous monitoring is required.

关键词

培唑帕尼药物不良事件信号挖掘药物不良反应比例失衡法

Keywords

adverse drug eventsignal miningadverse drug reactionproportional imbalance method

references

BRAY F，FERLAY J，SOERJOMATARAM I，et al. Global cancer statistics 2018：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin，2018，68（6）：394-424.

高硕泽，范光锐，杨恩广，等. 转移性肾透明细胞癌分子靶向及新型免疫治疗进展[J]. 医学综述，2020，26（20）：4032-4037.

陈莉，汪涌，祝广峰，等. 2020年欧洲泌尿协会肾癌诊断和治疗指南概要[J]. 现代泌尿外科杂志，2020，25（10）：927-932，946.

周莉，盛锡楠. 晚期肾癌的治疗规范：《CSCO肾癌诊疗指南2020》解读[J/OL]. 肿瘤综合治疗电子杂志，2020，6（4）：1-6，111[2022-12-20].https：//kns.cnki.net/KCMS/detail/detail.aspx?filename=ZLZD202004001&dbname=CJFD&dbcode=CJFQhttps://kns.cnki.net/KCMS/detail/detail.aspx?filename=ZLZD202004001&dbname=CJFD&dbcode=CJFQ.

刘海娇，吴玉霞，徐伟. 转移性肾癌一线治疗药物舒尼替尼、索拉非尼和培唑帕尼的药物经济学评价文献研究[J]. 中国药房，2020，31（5）：612-616.

王艳，吴晓玲，门鹏，等. 培唑帕尼治疗晚期/转移性肾细胞癌的有效性、安全性和经济性的快速卫生技术评估[J]. 中国新药杂志，2019，28（24）：3030-3034.

叶小飞. 上市后药品不良反应信号检测方法的进展与思考[J]. 海军军医大学学报，2022，43（2）：117-122.

陈晨，金子妍，胥昕怡，等. 阿昔替尼和依维莫司用于肾癌治疗的安全性比较：基于药物警戒数据库不良事件分析[J]. 肿瘤药学，2021，11（4）：385-393.

MIYAMOTO S，KAKUTANI S，SATO Y，et al. Drug review：pazopanib[J]. Jpn J Clin Oncol，2018，48（6）：503-513.

楼江. 培唑帕尼超说明书用药专家共识[J]. 中国现代应用药学，2021，38（8）：904-911.

李长岭，齐隽，陈立军，等. 晚期肾透明细胞癌一线靶向治疗的优化选择中国专家共识：2022[J]. 临床泌尿外科杂志，2022，37（5）：329-337.

韩俊伟，李元平，程瑶，等. 血管内皮生长因子受体酪氨酸激酶抑制剂致肿瘤患者发生严重胃肠道事件风险的网状meta分析[J]. 药物不良反应杂志，2022，24（3）：130-138.

中国医师协会外科医师分会胃肠道间质瘤诊疗专业委员会. 酪氨酸激酶抑制剂治疗胃肠间质瘤不良反应及处理中国专家共识：2022版[J]. 中华消化外科杂志，2022，21（8）：997-1013.

高彩云，靳鹏，苏凤云. 培唑帕尼致消化道出血的药学分析与监护[J]. 中国药师，2021，24（12）：2221-2224.

王芳，杨杰，黄芪. 帕唑帕尼治疗肿瘤疾病所致高血压和肝毒性的Meta分析[J]. 西南国防医药，2018，28（12）：1257-1259.

CHANG H M，OKWUOSA T M，SCARABELLI T，et al. Cardiovascular complications of cancer therapy：best practices in diagnosis，prevention，and management：part 2[J]. J Am Coll Cardiol，2017，70（20）：2552-2565.

TINNING A R，BENGTSEN C，JENSEN N V，et al. Pazopanib-induced hypertension in patients with renal cell carcinoma is associated with low urine excretion of NO metabolites[J]. Hypertension，2018，71（3）：473-480.

CAMARDA N，TRAVERS R，YANG V K，et al. VEGF receptor inhibitor-induced hypertension：emerging mechanisms and clinical implications[J]. Curr Oncol Rep，2022，24（4）：463-474.

夏云龙，刘飞. 抗肿瘤药物相关高血压的研究进展[J]. 临床心血管病杂志，2022，38（8）：609-613.

GADD M，PRANAVAN G，MALIK L. Association between tyrosine-kinase inhibitor induced hypertension and treatment outcomes in metastatic renal cancer[J]. Cancer Rep，2020，3（5）：e1275.

AGARWAL M，THAREJA N，BENJAMIN M，et al. Tyrosine kinase inhibitor-induced hypertension[J]. Curr Oncol Rep，2018，20（8）：65.

程军，汪龙. 帕唑帕尼致不良反应33例文献分析[J]. 中国新药杂志，2018，27（22）：2717-2720.

STUDENTOVA H，VOLAKOVA J，SPISAROVA M，et al. Severe tyrosine-kinase inhibitor induced liver injury in metastatic renal cell carcinoma patients：two case reports assessed for causality using the updated RUCAM and review of the literature[J]. BMC Gastroenterol，2022，22（1）：49.

MINGARD C，PAECH F，BOUITBIR J，et al. Mechanisms of toxicity associated with six tyrosine kinase inhibitors in human hepatocyte cell lines[J]. J Appl Toxicol，2018，38（3）：418-431.

KAPADIA S，HAPANI S，CHOUEIRI T K，et al. Risk of liver toxicity with the angiogenesis inhibitor pazopanib in cancer patients[J]. Acta Oncol，2013，52（6）：1202-1212.

王直滔，何玲芳，楼永海. 1例培唑帕尼片致重度肝损伤的病例分析与药学监护[J]. 药物流行病学杂志，2023，32（1）：116-120.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Signal mining and analysis of adverse drug events of abatacept based on FAERS database

Mining and analysis of lorlatinib-induced adverse drug event signals

Mining and analysis of the ADE signals of avapritinib based on FAERS database

Safety signal mining of FOLFOX scheme and FOLFIRI scheme-induced hepatotoxicity

Data-mining of Adverse Drug Events Signals for Tocilizumab Based on US FAERS Database

Related Author

ZONG Shangshang

YANG Xiaojuan

GAO Maowei

ZHOU Houfeng

TANG Mengjiao

WANG Lichen

PU Shiyun

HUANG Mengwen

Related Institution

Dept. of Pharmacy， General Hospital of Wanbei Coal Power Group

Office of Drug Clinical Trial Institutions， General Hospital of Wanbei Coal Power Group

Dept. of Pharmacy， Chengdu Fifth People’s Hospital

School of Pharmacy， Chengdu University of Traditional Chinese Medicine

College of Pharmacy， North Sichuan Medical College， Sichuan Nanchong

Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰